Antiplatelet Therapy in Acute Coronary Syndrome
https://doi.org/10.23934/2223-9022-2021-10-4-769-777
Abstract
Cardiovascular diseases are currently the most common causes of death worldwide, and most deaths from cardiovascular diseases are associated with coronary artery disease (CAD). CAD as a whole is a serious problem for the world’s population, and acute coronary syndrome (ACS) is associated with high morbidity, mortality and a great financial burden on the health care system. This is an urgent situation in which diagnostic and treatment measures must be performed as soon as possible from the moment of onset of the disease. Diagnosis of ACS begins with a thorough clinical assessment of the patient’s symptoms, electrocardiogram and blood troponin levels, as well as a history of the disease. Key components in the treatment of ACS include coronary revascularization when indicated and prompt initiation of adequate antiplatelet therapy. The presented literature review is devoted to the problems of adequate antiplatelet therapy in patients with ACS.
About the Authors
I. M. Kuzmina
N.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Healthcare Department
Russian Federation
Russian Federation
Candidate of Medical Sciences, Cardiologist, Head of the Scientific Department of Emergency Cardiology for Patients with Acute Myocardial Infarction,
3 Bolshaya Sukharevskaya Square, Moscow 129090
D. S. Markhuliya
N.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Healthcare Department
Russian Federation
Russian Federation
Anesthesiologist-resuscitator of the Department of Resuscitation and Intensive Care,
3 Bolshaya Sukharevskaya Square, Moscow 129090
K. A. Popugayev
N.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Healthcare Department
Russian Federation
Russian Federation
Doctor of Medical Sciences, Deputy Director – Head of the Regional Vascular Center,
3 Bolshaya Sukharevskaya Square, Moscow 129090
K. V. Kiselev
Health Information and Analytical Center
Russian Federation
Russian Federation
Senior Business Analyst,
21 bld. 1 Krasnogvardeisky 1-y pr., Moscow 123112
References
1. Camm AJ, Lüscher TF, Maurer G, Serruys PW. (eds.) ESC CardioMed. 3rd ed. Oxford University Press; 2018. https://doi.org/10.1093/med/9780198784906.001.0001
2. Zdravookhranenie v Rossii 2015: statisticheskiy sbornik. Moscow: Rosstat Publ.; 2015. (in Russ.)
3. Braunwald E, Morrow DA. Unstable Angina: Is It Time for a Requiem? Circulation. 2013;127(24):2452–2457. PMID: 23775194 https://doi.org/10.1161/CIRCULATIONAHA.113.001258
4. Sheridan PJ, Crossman DC. Critical review of unstable angina and nonST elevation myocardial infarction. Postgrad Med J. 2002;78(926):717– 726. PMID: 12509688 https://doi.org/10.1136/pmj.78.926.717
5. Basit H, Malik A, Huecker MR. Non ST Segment Elevation (NSTEMI) Myocardial Infarction. [Last Update: September 6, 2021]. StatPearls [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK513228/ [Accessed Nov 22, 2021].
6. Goyal A, Zeltser R. Unstable Angina. [Last Update: July 26, 2021]. StatPearls [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK442000/ [Accessed Nov 22, 2021].
7. Akbar H, Foth C, Kahloon RA, Mountfort S. Acute ST Elevation Myocardial Infarction. [Last Update: August 9, 2021]. StatPearls [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK532281/ [Accessed Nov 22, 2021].
8. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237–269. https://doi.org/10.1093/eurheartj/ehy462
9. Falk E, Shah PK, Fuster V. Coronary Plaque Disruption. Circulation. 1995;92(3):657–671. PMID: 7634481 https://doi.org/10.1161/01.CIR.92.3.657
10. Karagodin VP, Bobryshev YV, Orekhov AN. Inflammation, Immune Cells, Cytokines – Role in Atherogenesis. Patogenez. 2014;12(1):21–35. (in Russ.)
11. Aronov DM, Lupanov VP. Atherosclerosis and Coronary Heart Disease: Some Aspects of Pathogenesis. Journal of Atherosclerosis and Dyslipidemias. 2011;1(2):48–56. (in Russ.)
12. Crea F, Libby P. Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision Treatmen. Circulation. 2017;136(12):1155– 1166. PMID: 28923905 https://doi.org/10.1161/CIRCULATIONAHA.117 .029870
13. O’Gara PT, Kushner FG, Ascheim DD, Casey Jr DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of STelevation myocardial infarction: a report of the ACCF/AMA Task Force on Practice Guidelines. Circulation. 2013;127(4):e362–e425. PMID: 23247304 https://doi.org/10.1161/CIR.0b013e3182742cf6
14. Mekaj Y, Daci F, Mekaj A. New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism. Ther Clin Risk Manag. 2015;11:1449–1456. PMID: 26445544 https://doi.org/10.2147/TCRM.S92222
15. Layne K, Ferro A. Antiplatelet Therapy in Acute Coronary Syndrome. Eur Cardiol. 2017;12(1):33–37. PMID: 30416549 https://doi.org/10.15420/ecr.2016:34:2
16. Cattaneo M. ADP receptor antagonists. In: Michelson AD. (ed.) Platelets. 2nd ed. San Diego: Elsevier/Academic Press; 2007. Prt.5, Ch.61. p.1127– 1144. https://doi.org/10.1016/B978-012369367-9/50823-5
17. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–533. PMID: 11520521 https://doi.org/10.1016/s0140-6736(01)05701-4
18. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607– 1621. PMID: 16271642 https://doi.org/10.1016/S0140-6736(05)67660-X
19. Shuvanan R. Clopidogrel resistance: the way forward. Indian Heart J. 2014;66(5):530–534. PMID: 25443607 https://doi.org/10.1016/j.ihj.2014.08.012
20. Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol. 2010;56(18):1456–1462. PMID: 20832963 https://doi.org/10.1016/j.jacc.2010.03.100
21. Granger CB, Berger PB. Understanding the Adverse Effects of Ticagrelor in Practice. JAMA Cardiol. 2016;1(4):381–383. PMID: 27438332 https://doi.org/10.1001/jamacardio.2016.1018
22. Dellborg M, Bonaca MP, Storey RF, Steg PG, Kyung AI, Cohen M, et al. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUSTIMI 54. Eur Heart J Cardiovasc Pharmacother. 2019;5(4):200–206. PMID: 31218354 https://doi.org/10.1093/ehjcvp/pvz020
23. Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev. 2007;25(4):357–374. PMID: 18078435 https://doi.org/10.1111/j.1527-3466.2007.00027.x
24. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015. PMID:17982182 https://doi.org/10.1056/NEJMoa0706482
25. De Luca L, Capranzano P, Patti G, Parodi G. Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations. Am Heart J. 2016;176:44–52. PMID: 27264219 https://doi.org/10.1016/j.ahj.2016.03.006
26. Deerhake ME, Tricoci P. Vorapaxar: The Drug and its Applications. May 18, 2016. American college of cardiology. Available at: https://www.acc.org/latest-in-cardiology/articles/2016/05/18/13/58/vorapaxar [Accessed Nov 23, 2021].
27. Offermanns S. Activation of platelet function through G proteincoupled receptors. Circ Res. 2006;99(12):1293–1304. PMID: 17158345 https://doi.org/10.1161/01.RES.0000251742.71301.16
28. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur Heart J. 2002;23(18):1441–1448. PMID: 12208224 https://doi.org/10.1053/euhj.2002.3160
29. Quinn MJ, Plow EF, Topol EJ. Platelet Glycoprotein IIb/IIIa Inhibitors, Recognition of a Two-Edged Sword? Circulation. 2002;106(3):379–385. PMID: 12119257 https://doi.org/10.1161/01.CIR.0000019581.22812.B2
30. Eisen A, Bhatt DL Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting. Heart. 2017;103(11):871–884. PMID: 27888209 https://doi.org/10.1136/heartjnl-2015-309022
31. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. PMID: 28886621 https://doi.org/10.1093/eurheartj/ehx393
32. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502. PMID: 11519503 https://doi.org/10.1056/NEJMoa010746
33. Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389(10073):1025–1034. PMID: 28290994 https://doi.org/10.1016/S0140-6736(17)30397-5
34. Yeh RW, Secemsky EA, Kereiakes DJ, Normand S-LT, Gershlick AH, Cohen DJ, et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016;315(16):1735–1749. PMID: 27022822 https://doi.org/10.1001/jama.2016.3775
35. Sabouret P, Rushton-Smith SK, Kerneis M, Silvan J, Collet J-P, Montalescot G. Dual antiplatelet therapy: optimal timing, management, and duration. Eur Heart J Cardiovasc Pharmacother. 2015;1(3):198–204. PMID: 27533996 https://doi.org/10.1093/ehjcvp/pvv015
36. Wilson SJ, Newby DE, Dawson D, Irving J, Berry C. Duration of dual antiplatelet therapy in acute coronary syndrome. Heart. 2017;103(8):573–580. PMID: 28249994 https://doi.org/10.1136/heartjnl-2016-309871
37. Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J. 2017;38(11):804– 810. PMID: 28363222 https://doi.org/10.1093/eurheartj/ehw525
38. Shamraev RL, Ilyukhin OV, Ivanenko VV, Merzlyakov SG, Lopatin YuM. Consequences of escalation and de-escalation of double antiplatelet therapy in patients with acute coronary syndrome in real clinical practice. Russian Journal of Cardiology. 2019;(3):90–97. (in Russ.) https://doi.org/10.15829/1560-4071-2019-3-90-97
39. Kupka D, Sibbing D. De-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention. Korean Сirc J. 2018;48(10):863–872. https://doi.org/10.4070/kcj.2018.0255
40. Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, et al. International Expert Consensus on Switching Platelet P2Y12 ReceptorInhibiting Therapies. Circulation. 2017;136(20):1955–1975. PMID: 29084738 https://doi.org/10.1161/CIRCULATIONAHA.117.031164
41. Deharo P, Quilici J, Camoin-Jau L, Johnson TW, Bassez C, Bonnet G. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPICVASP Pre-Specified Analysis of the TOPIC Randomized Study. JACC Cardiovasc Interv. 2017;10(24):2560–2570. PMID: 29268886 https://doi.org/10.1016/j.jcin.2017.08.044
42. Angiolillo DJ, Saucedo JF, Deraad R, Frelinger AL, Gurbel PA, Costigan TM, et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol. 2010;56(13):1017–1023. PMID: 20846599 https://doi.org/10.1016/j.jacc.2010.02.072
43. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121(10):1188–1199. PMID: 20194878 https://doi.org/10.1161/CIRCULATIONAHA.109.919456
44. Bagai A, Wang Y, Wang TY, Curtis JP, Gurm HS, Shah B, et al. Inhospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. Circ Cardiovasc Interv. 2014;7(4):585–593. PMID: 25097196 https://doi.org/10.1161/CIRCINTERVENTIONS.114.001555
45. Kim H-S, Kang J, Hwang D, Han J-K, Yang H-M, Kang H-J, et al. Prasugrelbased de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOSTREDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet. 2020;396(10257):1079–1089. PMID: 32882163 https://doi.org/10.1016/S0140-6736(20)31791-8
46. Zettler ME, Peterson ED, McCoy LA, Effron MB, Anstrom KJ, Henry TD, et al. Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. Am Heart J. 2017;183:62–68. PMID: 27979043 https://doi.org/10.1016/j.ahj.2016.10.006
Review
For citations:
Kuzmina I.M., Markhuliya D.S., Popugayev K.A., Kiselev K.V. Antiplatelet Therapy in Acute Coronary Syndrome. Russian Sklifosovsky Journal "Emergency Medical Care". 2021;10(4):769-777. https://doi.org/10.23934/2223-9022-2021-10-4-769-777
Views:
791
Email this article 